T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
Management is scheduled to present on
About
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Company Contact:Darlene Deptula-Hicks ,T2 Biosystems SVP & Chief Financial Officer ddeptula@t2biosystems.com 603-553-5803 Media Contact:Matthew McKillip ,T2 Biosystems mmckillip@t2biosystems.com 518-577-3466 Investor Contact:Chris Brinzey , Westwicke Partners chris.brinzey@westwicke.com 339-970-2843